Physician profile
Daniel R Blizzard
NPI 1437194354
$1,163.81
in general payments reported to CMS, 2019-2025
14 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $176 · 2021: $243 · 2022: $146 · 2024: $74.67 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $513.27 | 2020-2025 | Wegovy |
| Lilly USA, LLC | $158.90 | 2020-2025 | Mounjaro, Zepbound |
| Alphatec Spine, INC | $147.42 | 2025 | Other - Miscellaneous |
| Amgen INC. | $89.99 | 2019-2025 | Repatha, Otezla |
| Globus Medical, INC. | $59.46 | 2019 | |
| Pfizer INC. | $57.81 | 2021-2025 | |
| Amarin Pharma, INC. | $25.00 | 2020 | |
| Abbott Laboratories | $19.15 | 2019 | |
| Optinose US, INC. | $17.87 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.49 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $17.18 | 2020 | |
| Aytu Biopharma, INC. | $15.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.77 | 2019 | |
| Esperion Therapeutics, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Blizzard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.